Evidence map›Paper›PMID 31152052›Full record

ArticleJournal of cell science2019

Migration through physical constraints is enabled by MAPK-induced cell softening via actin cytoskeleton re-organization.

Dominika A Rudzka, Giulia Spennati, David J McGarry, Ya-Hua Chim, Matthew Neilson, Aleksandra Ptak, June Munro, Gabriela Kalna, Ann Hedley, Daniela Moralli and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cell science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Elucidation of CKAP4-remodeled cell mechanics in driving metastasis of bladder cancer through aptamer-based target discovery.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  11. Article
  12. Article
  13. Effects of forces on chromatin.APL bioengineering · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Dominika A RudzkaCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Giulia SpennatiSchool of Engineering, University of Glasgow, Glasgow G12 8QQ, UK.
David J McGarryCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Ya-Hua ChimSchool of Engineering, University of Glasgow, Glasgow G12 8QQ, UK.
Matthew NeilsonCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Aleksandra PtakCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
June MunroCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Gabriela KalnaCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Ann HedleyCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Daniela MoralliWellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
Catherine GreenWellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
Susan MasonCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Karen BlythCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Margaret MullinElectron Microscopy Facility, Department of Chemistry, University of Glasgow, Glasgow G12 8QQ, UK.
Huabing YinSchool of Engineering, University of Glasgow, Glasgow G12 8QQ, UK.
Michael F OlsonCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK michael.olson@ryerson.ca.ORCID 0000-0003-3428-3507
Cancer Research UK · GBUniversity of Glasgow · GBCentre for Human Genetics · GB

Funding

Cancer Research UK A17196Cancer Research UK A18276Medical Research Council MR/M018776/1
6 · The paper itself

Abstract

Cancer cells are softer than the normal cells, and metastatic cells are even softer. These changes in biomechanical properties contribute to cancer progression by facilitating cell movement through physically constraining environments. To identify properties that enabled passage through physical constraints, cells that were more efficient at moving through narrow membrane micropores were selected from established cell lines. By examining micropore-selected human MDA MB 231 breast cancer and MDA MB 435 melanoma cancer cells, membrane fluidity and nuclear elasticity were excluded as primary contributors. Instead, reduced actin cytoskeleton anisotropy, focal adhesion density and cell stiffness were characteristics associated with efficient passage through constraints. By comparing transcriptomic profiles between the parental and selected populations, increased Ras/MAPK signalling was linked with cytoskeleton rearrangements and cell softening. MEK inhibitor treatment reversed the transcriptional, cytoskeleton, focal adhesion and elasticity changes. Conversely, expression of oncogenic KRas in parental MDA MB 231 cells, or oncogenic BRaf in parental MDA MB 435 cells, significantly reduced cell stiffness. These results reveal that MAPK signalling, in addition to tumour cell proliferation, has a significant role in regulating cell biomechanics.This article has an associated First Person interview with the first author of the paper.

Indexed as

Actin CytoskeletonAnisotropyBiomechanical PhenomenaCell Line, TumorCell MovementCell PlasticityCell ProliferationFocal AdhesionsHumansMAP Kinase Signaling SystemMelanomaMicropore FiltersNeoplasm InvasivenessNeoplasm MetastasisProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)BRAF protein, humanKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)CytoskeletonElasticityMAPKMotility

Identifiers

PMID31152052
PMCPMC6589089
OpenAlexW2947001584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.